Physician profile
Kenya Windley
NPI 1821483876
$6,651.31
in general payments reported to CMS, 2019-2025
23 companies · $231 in 2025
The $231 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $158 · 2021: $1,834 · 2022: $1,973 · 2023: $1,730 · 2024: $725 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,686.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,287.07 | 2021-2024 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,077.56 | 2020-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,041.44 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $891.33 | 2021-2024 | Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $722.18 | 2021-2025 | Lybalvi, Aristada |
| Corium, LLC | $276.46 | 2021-2024 | Azstarys |
| Almatica Pharma LLC | $240.91 | 2022-2024 | Loreev Xr |
| Neurocrine Biosciences, INC. | $239.90 | 2020-2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $164.57 | 2020-2024 | Uzedy, Austedo Xr |
| Vanda Pharmaceuticals INC. | $122.17 | 2021-2024 | Fanapt, Hetlioz |
| Eisai INC. | $94.21 | 2020-2022 | |
| Lundbeck LLC | $88.04 | 2022-2023 | Rexulti |
| Indivior INC. | $75.44 | 2023-2024 | Perseris |
| Sunovion Pharmaceuticals INC. | $61.54 | 2021-2022 | |
| Uswm, LLC | $51.71 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $48.09 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $37.93 | 2025 | Cobenfy |
| Allergan, INC. | $33.80 | 2020 | |
| Avanir Pharmaceuticals, INC. | $29.79 | 2021 | |
| Ironshore Pharmaceuticals INC. | $19.39 | 2020 | |
| Axsome Therapeutics, INC. | $18.04 | 2024 | Auvelity |
| Orexo US, INC. | $15.91 | 2024 | Zubsolv |
| Noven Therapeutics, LLC | $13.83 | 2024 | Xelstrym, Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenya Windley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.